Scholarlink

<p>In late 2023, the BA.2.86 and EG.5.1 SARS-CoV-2 variants co-circulated globally, raising concerns about enhanced immune evasion and altered replicative capacity. In this study, we assessed their virological characteristics using live viruses. We evaluated sensitivity to therapeutic monoclonal antibodies and antivirals targeting NSP5 and NSP12, and performed direct competition assays. BA.2.86 displayed a complete loss of neutralization by Sotrovimab, consistent with the presence of the K356T escape mutation, whereas EG.5.1 retained similar susceptibility to its XBB ancestor. Both variants remained sensitive to antiviral compounds, with no evidence of resistance-linked mutations. In vivo, BA.2.86 showed reduced replication in hamster lungs (3–4 log<sub>10</sub> reduction) and a moderate reduction in the upper respiratory airways, compared to an ancestral reference strain (B.1 D614G). Direct in vitro competition, in primary nasal cells, further confirmed the reduced fitness of BA.2.86 relative to EG.5.1. Altogether, these results underscore the limited replicative potential of BA.2.86 despite immune escape and emphasize the value of assessing emerging SARS-CoV-2 variants using native viruses.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Virological characterization of SARS-CoV-2 BA.2.86 variants by assessing antiviral susceptibility, in vivo infectivity and replicative fitness

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月12日

查看全文
  • Emilie Giraud,
  • Géraldine Piorkowski,
  • Jean-Sélim Driouich,
  • Ornéllie Bernadin,
  • Cyrielle Durand,
  • Magali Gilles,
  • Rayane Amaral,
  • Sylvie van der Werf,
  • Xavier de Lamballerie,
  • Fabrice Agou,
  • Antoine Nougairède,
  • Franck Touret

摘要

In late 2023, the BA.2.86 and EG.5.1 SARS-CoV-2 variants co-circulated globally, raising concerns about enhanced immune evasion and altered replicative capacity. In this study, we assessed their virological characteristics using live viruses. We evaluated sensitivity to therapeutic monoclonal antibodies and antivirals targeting NSP5 and NSP12, and performed direct competition assays. BA.2.86 displayed a complete loss of neutralization by Sotrovimab, consistent with the presence of the K356T escape mutation, whereas EG.5.1 retained similar susceptibility to its XBB ancestor. Both variants remained sensitive to antiviral compounds, with no evidence of resistance-linked mutations. In vivo, BA.2.86 showed reduced replication in hamster lungs (3–4 log10 reduction) and a moderate reduction in the upper respiratory airways, compared to an ancestral reference strain (B.1 D614G). Direct in vitro competition, in primary nasal cells, further confirmed the reduced fitness of BA.2.86 relative to EG.5.1. Altogether, these results underscore the limited replicative potential of BA.2.86 despite immune escape and emphasize the value of assessing emerging SARS-CoV-2 variants using native viruses.